A recent breakthrough in the treatment of NSCLC is Fumonertinib (AST2818), a third-generation EGFR TKI developed Allist Pharmaceuticals Co., Ltd of Shanghai, China. This evidence concerns the gene EGFR and non-small cell lung carcinoma.